NCT04958993 2022-02-25
A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
Shandong Cancer Hospital and Institute
Phase 1/2 Terminated
Shandong Cancer Hospital and Institute
M.D. Anderson Cancer Center